Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Osheiza Abdulmalik, PhD
Researcher Research Associate II
Perelman School of Medicine
University of Pennsylvania
Rivella Lab
3615 Civic Center Blvd
Room 316B
Abramson Research Center
Philadelphia, Pennsylvania, United States
Dr. Abdulmalik’s research interests broadly encompass the hemoglobinopathies and red blood cell disorders, with particular focus on sickle cell disease and beta-thalassemia. Though both disorders are consequences of simple genetic mutations, the implications of these mutations are inherently complex, and include significant morbidities, lifelong challenges, reduced quality of life, and early mortality in patients; as well as substantial healthcare burden on families, caregivers, and society in general.
Dr. Abdulmalik’s current research focuses on three modalities of countering disease pathophysiology. The first approach, in tandem with a multidisciplinary team of collaborators, utilizes medicinal chemistry and structural biology to design novel drugs that block the primary pathophysiology of sickle cell disease, i.e., the polymerization of sickle hemoglobin.
Representative Publications:
Crystal structure of carbonmonoxy sickle hemoglobin in R-state conformation
+myBinderRelated Content
-
Men with sickle cell disease show significant concerns over safety while being treated for vaso-occlusive crises: pr...Background: We undertook a large multisi...
-
Comparison of Adult and Adolescent Quality of Ambulatory and Emergency Care in Sickle Cell Disease: Ascq-Me and the ...Quality of care (QOC) has been anecdotal...
-
Children’s Hospital of MichiganThe Sickle Cell Center at the Children's...
-
Mona Robbins, PhDDr. Mona Robbins is an Associate Profess...
-
Donald B. Kohn, MDDr. Donald Kohn, MD, is a Distinguished ...
-
Children’s Hospital of WisconsinThe Sickle Cell Research Program at Chil...
-
Gene-Edited ‘Supercells’ Make Progress In Fight Against Sickle Cell DiseaseDoctors are reporting the first evidence...
